Wastewater-based estimation of the effective reproductive number of SARS-CoV-2

Authors: Jana S. Huisman (1,2,3*), Jérémie Scire (2,3), Lea Caduff (4), Xavier Fernandez-Cassi (5), Pravin Ganesanandamoorthy (4), Anina Kull (4), Andreas Scheidegger (4), Elyse Stachler (4), Alexandria B. Boehm (6), Bridgette Hughes (7), Alisha Knudson (7), Aaron Topol (7), Krista R. Wigginton (8), Marlene K. Wolfe (6), Tamar Kohn (5,†), Christoph Ort (4,†), Tanja Stadler (2,3,†), Timothy R. Julian (4,9,10,†)

Affiliations
1. Department of Environmental Systems Science, ETH Zurich, Swiss Federal Institute of Technology, Zurich, CH-8092, Switzerland
2. Swiss Institute of Bioinformatics, Lausanne, CH-1015, Switzerland
3. Department of Biosystems Science and Engineering, ETH Zurich, Swiss Federal Institute of Technology, Basel, CH-4058, Switzerland
4. Eawag, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, CH-8600, Switzerland
5. Laboratory of Environmental Chemistry, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, CH-1015, Switzerland
6. Department of Civil and Environmental Engineering, Stanford University, Stanford, 94305, California, United States of America
7. Verily Life Sciences, South San Francisco, 94080, California, United States of America
8. Department of Civil and Environmental Engineering, University of Michigan, Ann Arbor 48109, Michigan, United States of America
9. Swiss Tropical and Public Health Institute, Basel, CH-4051, Switzerland
10. University of Basel, Basel, CH-4055, Switzerland

†These authors contributed equally
*Corresponding author: Jana S. Huisman; jana.huisman@env.ethz.ch; CHN K16, Universitätsstrasse 16, 8092 Zürich, Switzerland

Competing financial interests
The authors declare they have no actual or potential competing financial interests.

Abstract:

Background:

The effective reproductive number, Re, is a critical indicator to monitor disease dynamics, inform regional and national policies, and estimate the effectiveness of interventions. It describes the average number of new infections caused by a single infectious person through time. To date, Re estimates are based on clinical data such as observed cases, hospitalizations, and/or deaths. These estimates are temporarily biased when clinical testing or reporting strategies change.

Objectives:

We show that the dynamics of SARS-CoV-2 RNA in wastewater can be used to estimate Re in near real-time, independent of clinical data and without the associated biases.

Methods:

We collected longitudinal measurements of SARS-CoV-2 RNA in wastewater in Zurich, CH, and San Jose (CA), USA. We combined this data with information on the temporal dynamics of shedding (the shedding load distribution) to estimate a time series proportional to the daily COVID-19 infection incidence. We estimated a wastewater-based Re from this incidence.

Results:

The method to estimate Re from wastewater works robustly on data from two different countries and two wastewater matrices. The resulting estimates are as similar to the Re estimates from case report data as Re estimates based on observed cases, hospitalizations, and deaths are among each other. We further provide details on the effect of sampling frequency and the shedding load distribution on the ability to infer Re.

Discussion:

To our knowledge, this is the first time Re has been estimated from wastewater. This method provides a low cost, rapid, and independent way to inform SARS-CoV-2 monitoring during the ongoing pandemic and is applicable to future wastewater-based epidemiology targeting other pathogens.

Introduction:

A critical quantity to monitor an ongoing epidemic is the effective reproductive number Re [1–4]. Re describes the time-varying average number of new infections caused by a single infectious person throughout the course of their infection. Typically, Re is estimated from case report data (hereafter referred to as R_{cc}), including the numbers of new clinical cases, hospitalizations, and deaths [1,3–5]. Here, we show that viral RNA concentrations measured in wastewater provide an independent data set to estimate Re (hereafter referred to as R_{ww}). This complements existing R_{cc} estimates to provide a more complete picture of transmission dynamics.

Re estimates for SARS-CoV-2 are used to inform regional and national policies [6,7]. The Re changes through time and reflects changes in the immune status of the population, policy, climate, and/or individual behaviors [1,2]. It can thus be used to estimate the effectiveness of non-pharmaceutical interventions in disease control [5,8–11]. However, R_{cc} estimates have some notable drawbacks. Most importantly, they depend on robust and accurate clinical case surveillance and reporting. Temporal changes in testing capacity, hospitalization criteria, or the definition of COVID-19-related deaths can bias the R_{cc} estimates [1,12]. These estimates are also

81 inferred with a delay: R_{cc} is estimable once the infections occurring on that day tested positive
82 and were reported as clinical cases [1,2]. This delay differs through time and space, yet is
83 necessary to accurately infer R_{cc}, thus complicating the simultaneous computation across
84 geographic regions. Wastewater data may provide an advantage over clinical case data in all
85 these aspects.
86
SARS-CoV-2 RNA measurements in wastewater can be used to understand COVID-19
epidemiology because infected individuals shed the virus into the sewer system throughout their
infection. During the COVID-19 pandemic, SARS-CoV-2 RNA has been repeatedly detected in
wastewater and sewage sludge globally [13–19], and measured RNA concentrations or loads
correlate with clinical case data [13–15,17]. Detection of SARS-CoV-2 RNA in the wastewater
implies there is at least one actively shedding infected person in the catchment served by the
sewer system. Compared to clinical testing, substantially fewer wastewater samples are
required to track changes in infection incidence at the community level. Wastewater data has
also been integrated into compartmental models of infectious disease transmission, allowing
estimation of epidemiological parameters including incidence and the basic reproductive
number R0 (which corresponds to the Re in a fully susceptible population at the start of an
outbreak) [20,21]. These model results are frequently validated against clinical case data, and the
good correspondence between both supports the use of SARS-CoV-2 RNA measurements in
wastewater to inform disease transmission dynamics. In addition, there are indications that the
wastewater may track transmission dynamics more truthfully than cases, especially when test
positivity is high [22].
103
Models relating SARS-CoV-2 RNA in wastewater to incidence or transmission rates are driven
by assumptions of virus excretion rates into the sewer system. Excretion (via feces, saliva,
and/or sputum) varies by individual and through time after infection. Generally, this can be
described using a shedding load profile, which captures both the temporal dynamics of
shedding (in the shedding load distribution; SLD), and the total amount of virus shed by an
infected individual. Clinical studies in various settings have measured shedding from symptom
onset onwards. Notable examples include Wölfel et al., who measured virus concentrations in
the stool of hospitalized patients [21,23] and Han et al., who included symptomatic and
asymptomatic children [24]. Benefield et al. combined such studies into a systematic review of
SARS-CoV-2 viral loads [25]. However, little is known about shedding prior to symptom onset.
Given uncertainty and variation in estimates of SLDs, modeling approaches to relate
wastewater to transmission have varied. For example, Kaplan et al. used an infectivity profile
(based on virus concentrations in the upper and lower respiratory tract from Li et al.) rather than
information on gastrointestinal shedding to estimate the basic reproductive number R0 from
wastewater data [20,26]. More work is needed to determine both the SLD and the amount of virus
shed during an infection to relate SARS-CoV-2 RNA measurements in wastewater to
epidemiology.
121
We measure SARS-CoV-2 RNA in sewage sludge or wastewater from two distinct monitoring
programs (Zurich, Switzerland and San Jose, CA, USA), use the measured RNA to estimate
R_{ww}, and compare the estimates to R_{cc} obtained from clinical case data. We further determine

the SLD that optimizes the fit between R_{ww} and R_{cc} and compare it to previously reported SLDs.
We find that R_{ww} is a useful metric to monitor the transmission dynamics of SARS-CoV-2,
independent from clinical case data. To our knowledge, this is the first time Re has been
estimated from pathogen concentrations in wastewater.
129

Methods:
SARS-CoV-2 RNA quantification in wastewater and primary sludge
<u>Overall approach.</u>
Longitudinal samples of raw wastewater influent from Zurich (Switzerland) and primary sludge
from San Jose (California, USA) were collected over several weeks from late 2020 through early
2021. Samples were concentrated, viral RNA was extracted, and SARS-CoV-2 RNA markers as
well as pepper mild mottle virus (PMMoV) RNA were quantified in each extract. PMMoV is a
plant virus that is found in wastewater at high concentrations and in fairly constant loads, and
serves to detect anomalies in the collected sample or problems during concentration and
extraction [27].
140

<u>Sample collection and processing</u>
Zurich approach. From 03 September 2020 to 19 January 2021, 24-hour flow-proportional
composite samples of raw influent (after fine screening) were collected from the Werdhölzli
wastewater treatment plant (Zurich, Switzerland). Samples were collected twice per week
(Thursdays, Sundays) until October 29; afterwards, samples were collected almost daily.
Samples were collected in 500 mL polystyrene or polypropylene plastic bottles, shipped on ice,
and stored at 4°C for up to 8 days before processing. Samples were processed following the
protocol of Fernandez-Cassi et al. 2021 [22]. Briefly, aliquots (50 mL) were stirred at room
temperature for 30 minutes and then clarified by sequential filtration through 2 µm glass fiber
pre-filters (Merck) and 0.22 µm SteriCup filters (Merck). The filtrates were concentrated by
centrifugation (3000x*g* for 30 minutes) using Centrifugal Filter Units (10kDa Centricon Plus-70,
Millipore, USA), followed by concentrate collection from the inverted filter during 3 min at
1000x*g*.
154

155   RNA was extracted from concentrates (140-280 µL) using the QiaAmp Viral RNA MiniKit
156   (Qiagen, USA) according to manufacturer's instructions, using 80 µL of eluate. Until 25 October,
157   samples were processed in duplicate (biological replicates). Samples were extracted once, and
158   a negative extraction control using molecular grade water was run in parallel for every batch of
159   extracted samples.
160

San Jose approach. From 15 November 2020 to 19 March 2021, 125 settled solids samples
(approximately 50 mL) were collected and processed daily from the primary settling tank at the
San Jose wastewater treatment plant (San Jose, CA, USA) using methods adapted from
Graham et al. and described in published protocols [15,28–30]. Briefly, 24-hour composite samples
were collected in clean plastic containers, immediately stored at 4°C, and transported to the lab
for initial processing within 6 hours of collection. The solids were dewatered by centrifugation at
24000x*g* for 30 minutes at 4°C. The supernatant was aspirated and discarded. A 0.5 - 1 g
aliquot of the dewatered solids was dried at 110°C for 19-24 hours to determine its dry weight.

Dewatered solids were resuspended in Bovine Coronavirus (BCoV)-spiked DNA/RNA Shield
(Zymo Research, Irvine, California, USA), to a concentration of 75 mg/mL. This concentration of
solids represented a concentration at which the PCR inhibition of the SARS-CoV-2 assays was
minimized based on experiments with solutions containing varying concentrations of solids (see
Supplemental Methods)[31]. BCoV was spiked as an external process control. To homogenize
samples, 5-10 5/32" Stainless Steel Grinding Balls (OPS Diagnostics) were added to each
sample before shaking with a Geno/Grinder 2010 (Spex SamplePrep). Samples were
subsequently briefly centrifuged to remove air bubbles introduced during the homogenization
process, and then vortexed to re-mix the sample. Samples were either further processed
immediately, or stored at 4°C for processing within 7 days.

RNA was extracted from 300 µL of homogenized sample using the Chemagic™ Viral DNA/RNA
300 Kit H96 for the Perkin Elmer Chemagic 360 into 60 µL of eluent followed by PCR Inhibitor
Removal with the Zymo OneStep-96 PCR Inhibitor Removal Kit [29]. Each sample was extracted
ten times. In addition, extraction negative and extraction positive controls, consisting of
approximately 500 copies of SARS-CoV-2 genomic RNA (ATCC), were extracted using the
same protocol as the homogenized samples in each batch of sample extraction.

<u>Quantification of viral targets</u>
Zurich approach. SARS-CoV-2 N gene markers N1 and N2 were quantified immediately or
within one week after RNA extraction (storage at -80°C) using digital RT-PCR (RT-dPCR). RT-
dPCR was performed on 5 µL RNA extract as template on either the Bio-Rad QX200 Droplet
Digital (01 September 2020 - 7 October 2020) with the One-Step RT-ddPCR Advanced Kit for
Probes (Bio-Rad CN 1864021) or Crystal Digital PCR using the Naica System (Stilla
Technologies, 8 October - 20 January 2021) with the qScript XLT 1-Step RT-PCR Kit
(QuantaBio CN 95132-500). SARS-CoV-2 N1 and N2 markers for the N gene were detected
using the 2019-nCoV CDC ddPCR Triplex Probe Assay (Assay ID dEXD28563542, Bio-Rad)
according to manufacturer's instructions, with proprietary primer and probe concentrations.
Primer and probe sequences are specified in Table S4, and further dPCR details in Table S5.

For samples processed on the Bio-Rad QX200, 20 µL reaction volumes were prepared in a pre-
reaction volume of 22 µL consisting of 5.5 µL of template, 5.5 µL of Supermix, 2.2 µL of
Reverse Transcriptase, 1.1 µL of DTT and 1.1 µL of 20x 2019-nCoV CDC ddPCR Triplex Probe
Assay. Droplets were generated using the QX100 Droplet Generator (Bio-Rad). PCR was
performed on the T100 Thermal Cycler (Bio-Rad) with the following protocol: hold at 25℃ for 3
minutes, reverse transcription at 50℃ for 60 minutes, enzyme activation at 95℃ for 10 minutes,
40 cycles of denaturation at 95℃ for 30 seconds and annealing and extension at 55℃ for 1
minute, enzyme deactivation at 98℃ for 10 minutes, and an indefinite hold at 4℃. Ramp rate
was 2℃/second, and the final hold at 4℃ was at least 30 minutes to stabilize droplets. Droplets
were analyzed using the QX200 Droplet Reader (Bio-Rad) and thresholding done on the
QuantaSoft Analysis Pro Software (Bio-Rad, Version 1.0).

For samples processed on the Crystal Digital PCR, 25 µL reactions were prepared in 27 µL pre-
reaction volumes for Sapphire Chips (Stilla Technologies CN C14012) consisting of 5.4 µL of

template, 13.5 μL of 2x qScript XLT One-Step RT-PCR, and 1.35 μL of 20x 2019-nCov CDC
ddPCR Triplex Probe Assay. Droplet production and PCR were performed on the Naica Geode
with the following protocol: reverse transcription at 48℃ for 50 minutes, denaturation at 94℃ for
3 minutes, followed by 40 cycles of denaturation at 94℃ for 30 seconds, annealing and
extension at 57℃ for 1 minute. Chips were read and analyzed on the Naica Prism3 using the
Crystal Reader and Crystal Miner software (Stilla Technologies).

For the Bio-Rad QX200 samples with more than 12000 droplets with average partitioning
volume of 1 nL were deemed acceptable. For the Stilla Crystal Digital PCR 15000 droplets with
average 0.8 nL were deemed acceptable. The average (standard deviation) number of droplets
observed in samples from QX200 was 15000 (2100) and for the Crystal Digital PCR excluding
controls was 24000 (2000). Average copies per partition (relative uncertainty) was 8.7×10^{-3}
(54%). Technical replicate variability was, on average, less than 20%. The variation amongst
distinct RT-dPCR runs (inter-experimental variation) was quantified as the coefficient of
variation in the performance of a positive control (100 gene copies (gc)/reaction of synthetic
SARS-CoV-2 RNA reference material; EURM-019, Joint Research Center) across 87 runs, and
was less than 25%. Assays were only conducted in one laboratory, so reproducibility was not
assessed. Example fluorescence plots are provided in the Supporting Information (Figures S11,
S12).
230
Samples were diluted 10-fold in a single step using molecular grade water before quantification
in replicate wells. In addition, every thermal cycler run included one positive control and one no
template control (NTC) consisting of RNAse/DNAse-free water. Thermal cycle runs and
associated samples were deemed acceptable if the NTCs in the run contained 2 or fewer
positive droplets, and there was detectable SARS-CoV-2 RNA in the positive controls. All RT-
dPCR runs fulfilled these criteria, with an average (standard deviation) concentration of the
positive controls of 101 (25) gc/reaction, in line with the target concentration. If the sample
concentration was below the limit of quantification (LOQ), an undiluted sample was quantified.
The limit of detection (LOD) and limit of quantification (LOQ) of the N1 and N2 markers were
determined by processing 10 replicates of synthetic SARS-CoV-2 RNA reference material at
target concentrations of 5, 8, 10, 25, 30, and 50 gc/reaction. The LOD was defined as the lowest
sample concentration distinguishable from the no template control in at least 8 out of 10
replicates (3 or more positive droplets). At this concentration, there would be a >95% likelihood
of detecting the target in at least one of the two technical replicates [32]. Using this criterion, LOD
was determined to be 8 gc/reaction (equivalent to 2560 gc/L wastewater)[32]. LOQ was
determined to be 25 gc/reaction (equivalent to 8000 gc/L wastewater), which was the lowest
concentration with coefficient of variation less than 25% [32]. When sample concentrations were
below the LOQ, samples were processed without dilution. Only one sample (September 20,
replicate B) remained below LOQ in both dilute and undilute samples (22.5 gc/reaction). This
sample was included in the analysis anyway.
251
To test PCR inhibition, the RT-dPCR was repeated using mastermix with a spiked internal
positive control consisting of 800 gc/reaction of synthetic SARS-CoV-2 RNA reference material
(EURM-019, Joint Research Center) so inhibition testing could be performed on the same assay

used for quantification.[33] Samples were added to the mastermix with a spiked internal control at
the same dilution used for quantification of the N1 and N2 markers. If either the observed N1 or
N2 concentration in the samples analyzed in mastermix with synthetic SARS-CoV-2 RNA was
80% or less than the sum of the concentration of SARS-CoV–2 RNA in the samples (unspiked)
plus the concentration in the sample-free, spiked internal positive control, then the samples
were considered inhibited. Inhibited samples were diluted 1:10, retested for SARS-CoV-2 as
well as inhibition using the same spiked internal positive control. Dilution sufficiently reduced
inhibition for all affected samples.

PMMoV was quantified by RT-qPCR using RNA UltraSense™ One-Step Quantitative RT-PCR
System (Applied Biosystems CN 11732927) on a LightCycler® 480 instrument (Roche Life
Science, Switzerland) using previously reported primers and probes (Microsynth AG,
Switzerland, Table S4)[34,35]. RNA extract aliquots that were separately stored at -80°C for less
than three months were used as template. Samples were prepared in 25 µL reaction volumes
consisting of 5 µL of template, 5 µL of 5x Ultrasense Mix, 4 µL of Bovine Serum Albumin
(Sigma-Aldrich CN 05470-1G) at 2 mg/mL concentration, 1.25 µL of Reverse Transcriptase, and
1 µL of each primer at final concentrations of 400 nM and 0.25 µL of probe at a final
concentration of 250 nM. The RT-qPCR was run with the following program: reverse
transcription at 55℃ for 60 minutes, denaturation at 95℃ for 10 minutes, followed by 45 cycles
of denaturation at 95℃ for 15 seconds, annealing and extension at 60℃ for 1 minute. PMMoV
quantification was performed in six separate RT-qPCR runs by comparison to synthetic DNA
standards (gBlock, IDT Technologies) run in duplicate at tenfold dilutions between $5x10^2$ (the
lowest concentration measured) and $5x10^7$ per 5 µL reaction. All thermal cycler runs were
pooled for analysis. The pooled standard curve had an amplification efficiency of 97.4% and a
goodness-of-fit (R^2) of 0.997.
279
San Jose approach. RNA extracts were used as template in RT-dPCR assays for SARS-CoV-2
N, S, and ORF1a RNA gene targets in a triplex assay, and PMMoV and BCoV in a duplex
assay. All primers and probes are listed in Table S4. The SARS-CoV-2 assays were designed
using Primer3Plus (https://primer3plus.com/) based on the genome of the severe acute
respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 (Accession Number MN908947.3).
The assay was designed to target product size range of 60-200 bp at concentration of dNTPs of
0.8 mM and concentration of divalent cations of 3.8 mM, based on the following optimum
(range) conditions: primer size: 20bp (15bp, 36bp); primer melting temperature 60℃ (50℃,
65℃); primer GC content: 50% (40%, 60%); hydrolysis probe size 20bp (15bp, 27bp); hydrolysis
probe melting temperature 63℃ (62℃, 70℃); hydrolysis probe GC content: 50% (30%, 80%).
The location (length) of the amplicons for N is 28287-28457 (171 bp), S is 23591-23665 (75 bp),
and ORF1a is 12885-13063 (179 bp). Cross-reactivity was determined in silico using NCBI
Blast. The assays were optimized by varying annealing temperature, and benchmarked against
a respiratory virus verification panel using extracted RNA. Limit of the Blank was determined
using negative nasal swab samples.
295
RT-dPCR was performed as previously described for the Bio-Rad QX200 analysis conducted in
Zurich using the One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad 1863021) with primers

(900 nM) and probes (250 nM) targeting N, S, and ORF1a RNA. Droplets were generated using
the AutoDG Automated Droplet Generator (Bio-Rad). PCR was performed using Mastercycler
Pro with the following protocol: reverse transcription at 50℃ for 60 minutes, enzyme activation
at 95℃ for 5 minutes, 40 cycles of denaturation at 95℃ for 30 seconds and annealing and
extension at either 59℃ (for SARS-CoV-2 assay) or 56℃ (for PMMoV/BCoV duplex assay) for
30 seconds, enzyme deactivation at 98℃ for 10 minutes then an indefinite hold at 4℃. The
ramp rate for temperature changes were set to 2℃/second and the final hold at 4℃ was
performed for a minimum of 30 minutes to allow the droplets to stabilize.
306
Droplets were analyzed using the QX200 Droplet Reader (Bio-Rad), with thresholding done
using QuantaSoft™ Analysis Pro Software (Bio-Rad, Version 1.0.596). The average (standard
deviation) number of droplets in ten merged wells determined from a random subset of ten
samples was 176000 (14500). Average (relative uncertainty) of the number of copies per
partition in the same subset was 3.2×10^{-3} (52%). As the samples were extracted ten times and
each extract analyzed in one well, technical replicate variability incorporates variation from both
RNA extraction and RT-dPCR. Sample errors estimated from the merged wells were <10%, in
line with coefficient of variation estimates of <8% for all three targets (S, N, ORF1a) in an
experiment of replicate (n = 97) positive controls at target concentrations of 400 gc/reaction.
Assays were conducted in only one lab, so reproducibility was not assessed. Example
fluorescence plots are provided in the associated reference by Topol et al.[30]. All liquid transfers
were performed using the Agilent Bravo (Agilent Technologies).
319
320   Undiluted extract was used for the SARS-CoV-2 assay template and a 1:100 dilution of the
321   extract (2 µL into 198 µL molecular grade water) was used for the PMMoV and BCoV assay
322   template. The 1:100 dilution is required since PMMoV is in high concentrations, and it is
323   important to be able to quantify the target and not saturate the number of positive partitions.
324
Each sample was run in 10 replicate wells, extraction negative controls were run in 7 wells, and
extraction positive controls in 1 well. In addition, PCR positive controls for SARS-CoV-2 RNA
were run in 1 well, and NTC were run in 7 wells. Results from replicate wells were merged for
analysis. Negative controls were required to have less than 2 droplets across all wells, PCR
positive controls were required to have ~200 positive droplets, and PCR positive extraction
controls were required to have ~ 50 positive droplets. If controls did not meet these acceptability
criteria, then the samples included on that plate were re-processed. Therefore, none of the
samples included in this study had controls that failed these acceptability criteria.
333
Data analysis and exclusion criteria
Zurich approach. Concentrations of RNA targets were multiplied by the daily flow rate to
estimate the total number of genome copies (gc) shed by people within the catchment per day
(referred to as loads and reported as gc/day). Samples with PMMoV loads outside the mean
plus or minus three times the standard deviation were considered as inconsistent with respect to
virus recovery and were excluded from further analysis. Inhibited samples were also removed
from further analysis.
341

342 *San Jose approach.* Concentrations of RNA targets were converted to concentrations per dry
343 weight of solids in units of gc/g dry weight. PMMoV was also used to monitor virus recovery in
344 the San Jose samples, using the same criteria as for the Zurich samples. BCoV was used to
345 assess virus recovery, and samples were removed from further analysis if the amount
346 recovered was less than 10% of the amount added.
347
Deconvolution by the Shedding Load Distribution
To relate the viral RNA loads or concentrations measured in wastewater to the number of new
infections per day, we used information on the profile of SARS-CoV-2 RNA shedding into the
wastewater by an infected individual in days after infection or symptom onset. In general, this
profile contains information about both the magnitude and timing of viral RNA shedding: (i) the
SLD $\sum_j w_j$ (a unitless distribution which sums to 1) describes the temporal dynamics of
shedding, and (ii) a normalization factor N describes the total amount of virus shed by an
infected individual during the course of infection (in units of gc/infection). After shedding,
downstream processes further affect the total amount of viral RNA sampled per infected
individual. We assume this does not affect the temporal dynamics, and can be summarised into
a second normalization factor M. In general, M will depend on the sewer system, the sampling
point within the wastewater treatment plant, choice of sample matrix and processing pipeline.
The units of M differ depending on the way viral concentrations were measured: in this study M
is unitless for Zurich, and day/g-dry weight for San Jose.
With these definitions, the measurement C_i of viral RNA in the wastewater on day *i* is related to
the past incidence of infections I_j on day *j*:

$$C_i = N \cdot M \sum_j w_{i-j} I_j \, ,$$

365 i.e. the observed wastewater measurements are a convolution of the daily infection incidence
366 with the SLD.
367
To obtain the infection incidence, we first filled gaps in the wastewater data through linear
interpolation, and smoothed it using local polynomial regression (LOESS) with 1st order
polynomials and tricubic weights that take into account 21 days of data around each point. To
deconvolve the resulting time series we used an Expectation-Maximisation algorithm [2], which
iteratively determines the time series I(t) that maximizes the likelihood of the smoothed
wastewater measurements $\bar{C}(t)$ (either in units of gc/day or gc/g-dry weight), given assumptions
on N, M, and $\sum_j w_j$.
375
For the main analysis, we deconvolved by a SLD which was a combination of the incubation
period (the time from infection to symptom onset) and the gastrointestinal SLD from Benefield et
al. for the time from symptom onset to shedding [25]. Figure 3 from Benefield et al. [25] was digitized
manually, and yielded a gamma distribution with mean 6.7 days and standard deviation 7.0
days [22]. For the incubation period, we used the distribution of Linton et al.: a gamma distribution
with mean 5.3 days and standard deviation 3.2 days [36]. For additional comparisons (Fig. S5,
S6), we exchanged the Benefield distribution for the SLD upon symptom onset reported by Han
et al., gamma distributed with mean 4.7 days, standard deviation 1.7 days [24], or the symptom

onset to death delay distribution from Linton et al., gamma distributed with mean 15 days,
standard deviation 6.9 days [36].
386
Since the normalization factors N and M are difficult to measure, and only influence R_{ww} point
estimates when off by several orders of magnitude (Fig. S6), we made a simplifying assumption.
We assumed the lowest measured RNA load (Zurich) or concentration (San Jose) represents
the viral load or concentration from a single infection (N*M). For the Zurich wastewater data, this
was $1*10^{12}$ gc per infection, and for the San Jose sewage sludge measurements this was
2663.7 gc/g-dry weight per infection/day.
393
Effective Reproductive Number Estimates
The effective reproductive number was estimated from SARS-CoV-2 RNA loads in wastewater
or concentrations in sewage sludge using the pipeline developed in Huisman *et al.* [2]. In brief, we
first transformed SARS-CoV-2 RNA measurements into a time series of infection incidence as
described in the Deconvolution section above. Second, we used the R package EpiEstim to
estimate the effective reproductive number Re from this infection incidence [4,37]. The pipeline
further accounts for noise in the observation process, by bootstrapping the observations prior to
smoothing and deconvolution. Specifically, we block-bootstrap the log-transformed residuals
between the linear interpolated original observations and the smoothed value [2].
403
To estimate R_{cc} for Zurich, we obtained the cases reported for the catchment from the Health
Department of Canton Zurich. We then used the pipeline from Huisman *et al.* [2], where we
deconvolved by a distribution specifying the delay from infection to case confirmation. This was
parameterized as the sum of a gamma distributed incubation period with mean 5.3 days,
standard deviation 3.2 days [36]; and a gamma distributed delay from symptom onset to case
confirmation with mean 2.8 days, standard deviation 3.0 days (estimated from line list data for
canton Zurich, Sep. 2020-Jan. 2021). The reported R_{cc} values for confirmed cases,
hospitalizations, and deaths at the cantonal level were taken from https://github.com/covid-19-
[Re/dailyRe-Data](https://github.com/covid-19-Re/dailyRe-Data) (based on Huisman *et al.*[2]). For the Swiss data, "case confirmation" refers to
the earliest recorded date of either a positive test or case reporting.
414
To estimate Rcc in San Jose, we downloaded daily COVID-19 case incidence data for Santa
Clara County from the California Health and Human Services Open Data portal
(https://data.chhs.ca.gov/dataset/covid-19-time-series-metrics-by-county-and-state). The
wastewater from Santa Clara County (population of 1.7 million) is nearly all treated at the San
Jose wastewater treatment plant (catchment population of 1.5 million). We estimated R_{cc} using
the pipeline from Huisman *et al.* [2], with the incubation period as before [36]; and a gamma
distributed symptom onset to case reporting delay distribution with a mean of 4.51 days and
standard deviation of 3.16 days (estimated from line list data for Santa Clara County in
December; based on personal correspondence with the California Department of Public Health
COVID-19 modelling team). During the study period, the mean of this distribution changed from
5.24 to 3.31 days, and the standard deviation from 3.55 to 2.32 days. Negative numbers of
cases reported (Dec. 30) were set to 0 for the main analysis (Fig. 2), and to 1000 to test the
impact of misreporting (Fig. S2).

To estimate Re for the testing-adjusted cases, we extracted the daily number of positive tests /

total number of tests, multiplied by the mean number of tests during the time period (14960.3).

This time series was then used to estimate Re, similar to the confirmed cases (with the same

delay distribution) [2]. Technically, the tests are reported by testing date, which typically precedes

the reporting date, so this constitutes a misspecification of the delay distribution. However, an

analysis where the delay between symptom onset and testing was assumed 0 did not yield

qualitatively different results (Fig. S1). We additionally compared our estimates to the R_{cc}

estimates for Santa Clara County from the California COVID assessment tool

(https://calcat.covid19.ca.gov/cacovidmodels/).

Comparing Re traces

We assessed how well the Re estimates from SARS-CoV-2 concentrations in wastewater (R_{ww})

match those estimated from case report data (R_{cc}) using several measures. First, the average

root mean squared error between both point estimates across the time series ("RMSE"):

$$\sqrt{\frac{1}{K}\sum_{j=1}^{K}\left(R_{ww,j} - R_{cc,j}\right)^2} \; ,$$

444   where j describes the date, and K the length of the time series. Second, the fraction of dates

445   where the R_{ww} point estimate was within the confidence interval of the R_{cc} estimate ("coverage").

446   Third, the mean average percentage error between the time series ("MAPE"):

$$\frac{1}{K}\sum_{j=1}^{K}\left|\frac{R_{cc,j} - R_{ww,j}}{R_{cc,j}}\right|.$$

Scanning across shedding load distributions

To investigate optimal parameters for the SLD, we conducted two separate scans. In the first

scan, we varied the parameters of the SLD from infection. In the second scan, we estimated the

parameters of the SLD from symptom onset onwards. In the latter case, the delay sampled from

the SLD was added to a second sampled delay corresponding to the incubation period (gamma

distributed with mean 5.3 days and standard deviation of 3.2 days) [36]. In both cases, we

assumed the SLD was described by a gamma distribution, and varied the mean μ and standard

deviation σ on a grid (μ ∈ {0.5, 1.0, ..., 15} and σ ∈ {0.5, 1.0, ..., 10}). The normalization factor

(N*M) was kept fixed to the location-specific value throughout. The R_{ww} for the wastewater data

was estimated across 50 bootstrap samples and compared to the R_{cc} for the catchment.

Availability Statement

All code and case data for Zurich are publicly available through the Github repository

https://github.com/JSHuisman/wastewaterRe. Wastewater measurements and daily flow rates

for Zurich are available at DOI: 10.25678/0003VC. Measurements from San Jose are available

from the Stanford Data Repository https://purl.stanford.edu/bx987vn9177 [31], and case data for

Santa Clara County is available from the California Health and Human Services Open Data

portal (https://data.chhs.ca.gov/dataset/covid-19-time-series-metrics-by-county-and-state).

Approval
No ethics approval was required for this study as no humans or animals were involved.
469

Results:
471 **SARS-CoV-2 RNA in Wastewater.** We tracked SARS-CoV-2 RNA concentrations in Zurich,
472 Switzerland and San Jose, California, USA during a rise and fall in clinical COVID-19 cases
473 (Fig. 1A,B; Fig. 2A,B). Data from Zurich were used to develop and assess R_{ww} estimates, and
474 data from San Jose were used to assess the generalizability of the approach.
475

In Zurich, SARS-CoV-2 N1 and N2 markers of the N gene were detectable in the raw influent
samples from the Zurich wastewater treatment plant between 1 September 2020 and 19
January 2021 in all 99 samples collected (Fig. 1A). Of these, the average of the technical
replicates was above the limit of quantification in 97, yielding median [range] loads of 13.4 [<12
(limit of detection), 13.7] $\log_{10}$ gc/day (Fig. 1A). Two samples (11 and 29 October 2020) were
excluded based on quality control, which included monitoring sample inhibition and consistency
of effluent pepper mild mottle virus (PMMoV) loads.
483

In San Jose, SARS-CoV-2 N, S, and ORF1a genes were quantifiable in the settled solids of the
primary settling tank in all 125 samples collected between 15 November 2020 and 19 March
2021 (Fig. 2A). The median [range] concentrations were 4.9 [3.4, 6.0], 5.0 [3.9, 6.0], and 5.0
[3.8, 6.0] $\log_{10}$ gene copies per gram dry weight (gc/g-dry weight) for N, S, and ORF1a genes,
respectively (Fig. 2A). Three samples (03 January, 18 February, 19 March 2021) were excluded
based on quality control using consistency of PMMoV concentrations.
490

491 Details pertaining to PMMoV measurements in all samples and resulting sample exclusion are
492 given in the Supplemental Results.
493

Inferring the infection incidence dynamics. Next, we related the RNA measurements in
wastewater to the original infection incidence by applying a deconvolution with the shedding
load distribution. SARS-CoV-2 wastewater measurements reflect the cumulative contributions of
all infected individuals actively shedding virus into the wastewater. The amount of virus shed by
each individual varies through time after infection, and is captured in the shedding load profile.
In general, this profile contains information about the timing of viral shedding - the shedding load
distribution (SLD; which sums to 1) - and the total amount of virus shed - captured by a
normalization factor N. To estimate the true number of infections in the sewer shed it is
important to estimate the exact value of the normalization factor N, as well as a factor M
describing losses along the way from shedding to sample processing. However, to estimate Re
it suffices to know the temporal dynamics of shedding and infection (described in more detail in
the Methods). As a first approximation, we assumed individuals do not shed prior to symptom
onset, and thereafter shed according to the gastrointestinal SLD reported by Benefield et al. [25].
With this assumption, we found that the dynamics of infection incidence inferred from
wastewater measurements in Zurich are similar to the dynamics inferred from clinical case data
(Fig. 1C). In particular, both data sources show a steep increase starting from mid-September,
and capture two peaks (indicative of Re=1) around late October and early December, each of

which is followed by relatively rapid decline in daily case incidence. We later test the sensitivity
of our results to the assumed SLD and normalization.
513
Estimating the effective reproductive number R_{ww} from wastewater measurements. We
used the inferred time series of infection incidence from SARS-CoV-2 RNA measured in
wastewater to estimate R_{ww} in Zurich (Fig. 1D). The N1 and N2 markers result in nearly identical
R_{ww} estimates, and there is a good correspondence between R_{ww} and R_{cc}. Both estimates show
a rapid increase up to Re = 1.5 in mid-September, a decline to below 1 in late October, followed
by a period where Re was slightly above 1 until dropping more clearly below 1 from early
December onwards. R_{ww} and R_{cc} are changing in similar ways, with R_{cc} lagging the R_{ww}
trajectory. Since both estimates describe the same underlying epidemic, this suggests that the
wastewater measurements may be deconvolved too far back in time (the mean of the SLD is
too high), or that the confirmed cases are not deconvolved back far enough (the mean of the
delay distribution is too low).
525
Over the entire time period, the average root mean squared error (RMSE) between R_{ww} and R_{cc}
is 0.11 and 0.12 for N1 and N2 respectively. This is smaller than the RMSE between the Re
estimates based on different sources of case report data: 0.13 between confirmed cases and
hospitalizations; and 0.26 between confirmed cases and deaths (estimated on case report data
from canton Zurich, which has a population 3.4x the size of the catchment, for the same time
period as R_{ww}).
532

533
Fig. 1: R$_{ww}$ estimation from Zurich (CHE) wastewater measurements. *(A) Measured RNA
loads of the N1 and N2 markers (green and yellow respectively) between 1 September 2020
and 19 January 2021. Imputed values are indicated in grey. (B) Confirmed cases (purple) in the
catchment during the same time period. (C) The estimated infection incidence in the catchment
per day from normalized RNA loads of the N1 and N2 markers (top; green and yellow
respectively), and case reports (bottom; purple). The measured loads were normalized by the
lowest measured value (N*M = 1*10^{12} gc per infection). The ribbons indicate the mean ±*

541 *standard deviation across 1000 bootstrap replicates. (D) The estimated R_{ww} compared to the R_{cc}*
542 *from confirmed cases. The colored line indicates the point estimate on the original data, and the*
543 *ribbons the 95% confidence interval across 1000 bootstrap replicates. The N1 and N2-based*
544 *confidence intervals nearly completely overlap.*

545
546 **Fig. 2: R_{ww} estimation from San Jose (USA) sludge measurements:** *(A) Measured RNA*
547 *concentrations of the N, S and ORF1a genes (blue, green, yellow respectively) between 15*
548 *November 2020 and 19 March 2021. (B, C) Confirmed cases and testing-adjusted cases in*
549 *Santa Clara county (purple, red) during the same time period. The testing-adjusted cases*

Application to an independent data source and different wastewater matrix. To test
whether these results could be generalized to different geographic locations and wastewater
matrices, we analyzed daily-sampled primary sewage sludge data from the San Jose
wastewater treatment plant in California.

In San Jose, the inferred infection incidence curves between confirmed cases and wastewater
data follow similar trends (Fig. 2D). The inferred incidence from confirmed cases rises rapidly,
reaching a maximum and fluctuating at a plateau throughout December. This fluctuation seems
primarily caused by reporting errors on Dec. 30th, as it fully disappears when replacing the 0
cases reported that day by 1000 (Fig. S2). Instead, wastewater estimates continue to rise more
gradually throughout December, similar to the cases adjusted for test-positivity. Starting in late
December, all traces show a similar decrease.

We found that R_{ww} agreed with R_{cc}, although there is again some temporal lag between both,
which seems more pronounced in November/December than in the second half of the time
series (Fig. 2D). The Re estimates based on the testing-adjusted cases are more comparable to
R_{ww}, both in terms of slope (especially in December) and a more uniform delay throughout the
entire time period. This further suggests that the R_{cc} estimates are biased by underreporting and
increased testing delays, and not as trustworthy as R_{ww} in this case. A comparison between R_{cc}
estimated using different methods (as reported on the website of the California State
Department of Public Health) shows substantially larger differences than between the
wastewater and the confirmed case estimates from the same pipeline (Fig. S3).

Minimal Frequency of Wastewater Sampling needed to inform R_{ww}. While designing
wastewater-based epidemiology studies, an important cost-benefit trade-off centers around the
frequency of sampling. We subsampled the daily sampled wastewater measurements in Zurich
and San Jose, prior to the Re estimation pipeline, to determine how this would affect the
estimated R_{ww}. We assessed a range of sampling strategies that differed in the number and
identity of the days sampled (e.g. Mon-Wed-Fri or Tue-Fri). For Zurich, we restricted ourselves
to the period with daily sampling (22 November 2020 to 11 January 2021). Using the RMSE to
quantify the similarity between different R_{ww} estimates, we found that subsampling down to 3
measurements per week still leads to results comparable to a daily sampling regime (Fig. S4,
Table S1, Table S2). However, below this frequency the representativity of the R_{ww} estimate
starts to depend on which days were sampled.

Susceptibility of R_{ww} estimates to the shedding load distribution. We showed that Re can
be estimated from RNA measurements in wastewater, given an assumption for the SLD.
However, there is substantial variation between SLDs described in the literature, across
patients, bodily fluids, and geographic locations. The shape of the SLD, in particular the mean of
the gamma distribution used, affects the inferred timing of peak infection incidence (with larger
means shifting the incidence further back in time; Fig. S5). In our pipeline, we also observe that
smaller normalization factors N*M increase the amplitude of the estimated R_{ww}, albeit only when
mis-specified by more than 5 orders of magnitude (Fig. S6). In principle, the inference of the Re
point estimate from an infection incidence is independent of the magnitude of this incidence [2,4].
However, the expectation maximization algorithm used for deconvolution in our pipeline was
optimized for data on the scale of infections per day. Here, we have chosen to normalize the
wastewater measurements such that the considered gene loads are on that same scale, since
R_{ww} otherwise reacts too strongly to changes in the daily incidence.

**Estimating the shedding load distribution from the fit between clinical and wastewater
data.** Instead of assuming a single SLD and estimating R_{ww} based only on that distribution, we
also asked which SLD would maximize the similarity between the R_{ww} and R_{cc} estimates. We
numerically scanned across different SLDs and quantified the resulting goodness of fit between
the R_{ww} and R_{cc} for both Zurich and San Jose. We assumed the SLD is described by a single
gamma distribution, starting at infection, and searched for the optimal fit on a grid of mean-
standard deviation parameter pairs (Table 1, Fig. 3). The fit was quantified using the root mean
squared error (RMSE), coverage, and mean absolute percentage error (MAPE). Since the
measurements of the different genetic markers followed nearly identical patterns in both
locations (Figs. 1 and 2), we conducted the SLD optimization analysis only for the N1 marker in
Zurich, and S gene in San Jose.

The optimal fits based on these metrics suggest that the SLD has a mean between 7-11 days in
Zurich and 5-7 days in San Jose, with a very low standard deviation of 0.5 days in both
locations (Table 1). However, there is some non-identifiability in our analysis, with most optimal
value pairs lying along a ridge (Fig. 3; repeated for coverage: S7, and MAPE: S8). This ridge
corresponds to SLDs with a similar median, which result in nearly indistinguishable R_{ww}
estimates (examples shown in Fig. S9). If we consider the parameters yielding a fit within 10%
from the optimum, the parameter ranges found in both locations are compatible and jointly
suggest an SLD with mean between 6-9 days, and standard deviation between 0.5-3 days.
Longer time series and more locations would further constrain this distribution. Compared to the
delay between infection and case reporting, the SLD introduces a similar or lower mean delay to
R_{ww}. For Zurich, the cases were delayed with respect to infection by 8.1 days on average, which
is comparable to the 6-9 days for R_{ww}. For San Jose, instead, the delay distribution of the case
report data had a mean of 9.8 days. There, the wastewater may lead the confirmed cases by 1-
4 days, if the current testing and reporting regime is upheld.

To compare against published SLDs, which are frequently parameterized from symptom onset
instead of infection, we conducted a second analysis. Here we assumed individuals do not shed

during their incubation period and subsequently shed with a gamma distribution, starting at
symptom onset. In this case, we find optimal SLDs with a mean between 0.5-3 days for San
Jose and 3.5-5.5 days for Zurich (Table S3, Fig. S10). These optimal distributions have a lower
mean than the SLD reported by Benefield et al. (mean 6.7 days), and Han et al. (mean 4.7
days) [24,25]. If we add the mean incubation period (5.3 days) to the results of this scan, we find
that for both locations the mean delay between infection and shedding is comparable to the
mean of the SLD we estimated from infection.
645

646
Fig. 3: RMSE between R_{cc} and R_{ww} for different shedding load distributions. *We scanned*
across different parameter pairs (mean, standard deviation in days) for the SLD from time since
infection. For the city of Zurich, the R_{ww} from N1 loads in wastewater was compared to that of
confirmed cases in the catchment. For San Jose, we compared S gene concentrations to
confirmed cases in Santa Clara County. The contour lines show SLD parameter pairs with equal
RMSE, in steps of 10% of the optimum value.
653

Comparison Method	Optimal pair (mean; sd)	Mean within 10% from the optimum	SD within 10% from the optimum
RMSE (Zurich)	(7.5; 0.5)	[6, 11.5]	[0.5, 10]
Coverage (Zurich)	(7.5; 0.5)	[6, 12.5]	[0.5, 10]
MAPE (Zurich)	(11; 9.5)	[6.5, 11]	[0.5, 10]
RMSE (San Jose)	(7.0; 0.5)	[6, 9]	[0.5, 3]
Coverage (San Jose)	(5; 0.5)	[1, 11]	[0.5, 10]
MAPE (San Jose)	(6; 0.5)	[5, 8]	[0.5, 2.5]

654
Table 1: Parameters of the optimal shedding distribution from infection. *We scanned*
across different (mean, standard deviation) parameter pairs for the SLD from time since
infection. For Zurich, the Re from N1 loads in wastewater was compared to that of confirmed
cases in the catchment. For San Jose, we compared S gene concentrations to confirmed cases

in Santa Clara County. For all values of the scan see Figs. 3, S7, S8. All parameters are in units
of days. For the coverage, the 95% confidence intervals of R_{cc} and R_{ww} were based on 50
bootstrap replicates in each comparison.
662

Discussion:

We showed that regular measurements of SARS-CoV-2 concentrations in wastewater and
settled solids can be used to estimate the effective reproductive number Re. The difference
between Re estimates from wastewater (R_{ww}) and from case report data (R_{cc}) is similar to the
difference between Re estimates based on different types of case report data (clinical cases,
hospitalizations, and deaths). This did not depend on which of the measured gene targets was
used to estimate R_{ww}. We further showed wastewater samples should be collected at least 3
times per week to reliably estimate past R_{ww}, in line with analyses based on direct comparison
of wastewater signals to clinical cases [15,38]. For real-time monitoring of R_{ww}, more frequent
measurements may be preferable to ensure stable estimates when new data comes in.
673

Estimating R_{ww} requires accurate characterization of the SLD, i.e. the temporal dynamics of
shedding. In our primary analysis, we used the distribution for gastrointestinal shedding from
Benefield et al. [25]. In using this SLD, we implicitly assumed that fecal shedding dominates the
viral load in wastewater. However, there is a wide range in published viral shedding loads, and it
is unclear which - if any - accurately capture viral shedding dynamics of people within a
catchment. Virus shed in saliva, sputum, and feces are possible contributors to the total amount
of virus RNA in the wastewater [39]. While upper respiratory tract swabs show peak viral loads
around the day of symptom onset, there are indications that sputum samples peak a few days
later, and feces even after that [40–42]. Studies differ in the inferred timing of peak viral load (even
in the same bodily fluids), and there is a general lack of information to constrain dynamics prior
to symptom onset [43]. Additionally, the duration and magnitude of viral shedding seem to differ
within different populations (for example, due to age or severity of disease) [44,45]. However, these
individual differences will probably average out in a sufficiently large catchment and better
estimates of the SLD are likely to become available as prospective sampling studies report
results.
689

We showed that the optimal SLD can also be inferred from the fit between R_{ww} and R_{cc}. Once
the SLD has been estimated from historic wastewater and case data, it may from then on
provide a more accurate estimation of R_{ww}, than using one of the published SLDs. Indeed, here
we show a range of gamma-distributed SLDs inferred from our wastewater data that generally
align with, but have lower means than published SLDs based on patient shedding profiles.
Optimization based on alignment between R_{ww} and R_{cc} assumes accuracy of R_{cc}, which only
holds when there is adequate clinical case surveillance. However, given widespread wastewater
monitoring coincident to clinical case reporting, broader application of our methods would help
constrain the SLD of SARS-CoV-2.
699

The utility of wastewater measurements for Re estimation is independent of the pipeline used to
estimate Re. Here, we report results obtained with the pipeline of Huisman et al. [2]. However,
many estimation methods exist, differing in assumptions on smoothing, deconvolution,

uncertainty quantification as well as the underlying method to estimate Re from infection
incidence [1,3,7,46,47]. Although the Re point estimate is not affected by the absolute magnitude of
the infection incidence (and thus comparable across wastewater treatment plants with differing
sampling protocols), the rest of our pipeline (in particular the deconvolution) was originally
developed specifically for use with clinical data. Thus, we had to normalize the measured
wastewater concentrations to the same order of magnitude as the case data. Further
development could make the method more specifically adapted to wastewater data, and
alleviate this dependence on the normalization.
711
Estimates of R_{ww} are independent of biases influencing clinical case-based estimates. R_{cc}
estimates are based on only the subset of infections, hospitalizations, and/or deaths that are
captured by surveillance within the healthcare system. If this subset changes, for instance due
to developments in testing or reporting policy, the resulting R_{cc} estimates will be temporarily
biased [2,4]. In Geneva, Switzerland, seroprevalence studies showed that the number of infections
per reported case varied substantially, from an estimated 11.6 infections per reported case as of
May 2020 to only 2.7 as of December 2020 [48,49]. During that period, SARS-CoV-2 RNA
concentrations in wastewater better reflected the dynamics than the clinical cases [22].
720
However, R_{ww} estimates are also prone to biases. People's behaviors, such as defecation timing
outside of a daily routine [50] and/or movement into or out of the catchment [51] can influence R_{ww}
estimates, particularly when the number of infected individuals is low. RNA signals may also be
impacted during sewer transport, with persistence influenced by environmental conditions (i.e.,
temperature) and/or sewage composition (i.e., solids content) [52–55]. Furthermore, sample
processing required to quantify SARS-CoV-2 RNA may introduce variation, as suggested by
substantial day-to-day variation in measurements [13,15,22,56]. Finally, R_{ww} estimates are informed
by the number and proportion of infected and/or shedding people within the catchment: if there
are too few active shedders, R_{ww} may be very sensitive to the increased fluctuations in SARS-
CoV-2 RNA concentrations.
731
To conclude, deriving Re from wastewater offers an independent method to track disease
dynamics. Wastewater-based epidemiology is used globally to track the COVID-19 pandemic
(https://www.covid19wbec.org/covidpoops19) [13–19]. The data collected within these campaigns
could be used to estimate R_{ww} with a robust method, not influenced by heterogeneous testing
and reporting strategies, and hence more comparable across geographic areas. Additionally,
R_{ww} estimates could be derived for the transmission of SARS-CoV-2 variants and/or other
pathogens for which SLDs are known. SARS-CoV-2 variants, including Variants of Concern
(VOCs), are readily detectable in wastewater [57–59] as are other pathogens (e.g., norovirus,
enterovirus, hepatitis A) [60–62]. This could provide the temporal, quantitative wastewater
measurements needed to estimate R_{ww}. Wastewater surveillance allows estimating R_{ww} to track
disease transmission dynamics in near-real time, using low cost, rapid, and geographically-
comparable methods, and can be used when reporting clinical cases is not feasible, mandatory,
or much delayed compared to infection and shedding.
745
746

Acknowledgements:

We thank members from the Bonhoeffer and Stadler groups for helpful discussions, Carola Bänziger (Eawag), Claudia Scheckel (Oncobit AG, Switzerland), and Bruno Mueller and Sergey Yakushev (Microsynth AG, Switzerland) for assistance with and/or knowledge exchange on method development. We further thank the operators of the Zurich WWTP for providing samples; Alexander J. Devaux and Charlie Gan for their help in analyzing the Zurich samples; the staff of the San Jose WWTP including Payak Sarkar, Noel Enoki, and Amy Wong; the Health Department of Canton Zurich for catchment-specific case numbers; and the California Department of Public Health Covid-19 modelling team for input on the Re estimates and symptom onset to case confirmation delay distribution for the state of California. We thank the reviewers for their suggestions to improve the manuscript. XFC, TS, CO, TRJ and TK acknowledge funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196538). CO, TRJ and TK further acknowledge discretionary funding from Eawag and EPFL. XFC was a fellow of the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska–Curie Grant Agreement No. 754462. The San Jose wastewater data acquisition and curation was funded by the CDC-Foundation.

Author contributions:

JSH, TK, CO, TS, TRJ conceived the study; JSH developed the analytical framework, designed and performed computational analyses; JS, AS, TS contributed to the analytical methods; LC, XFC, PG, AKu, ES, ABB, BH, AKn, AT, KRW, MKW, TK, CO, TRJ developed experimental protocols and performed wastewater sampling; XFC, ABB, KRW, TK, CO, TS, TRJ supervised the study and secured funding; JSH, TK, TRJ wrote the original draft; all authors reviewed and approved the final manuscript.

References:

1. Gostic KM, McGough L, Baskerville EB, et al. Practical considerations for measuring the effective reproductive number, R t. *PLoS Comput Biol*. 2020;16(12):e1008409.

2. Huisman JS, Scire J, Angst DC, Neher RA, Bonhoeffer S, Stadler T. Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2. *medrxiv*. Published online 2020. https://www.medrxiv.org/content/10.1101/2020.11.26.20239368v1.abstract

3. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. *Am J Epidemiol*. 2004;160(6):509-516.

4. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate time-varying reproduction numbers during epidemics. *Am J Epidemiol*. 2013;178(9):1505-1512.

5. Brauner JM, Mindermann S, Sharma M, et al. Inferring the effectiveness of government interventions against COVID-19. *Science*. 2021;371(6531). doi:10.1126/science.abd9338

6. Der Schweizerische Bundesrat. *Verordnung über Massnahmen in Der Besonderen Lage Zur Bekämpfung Der Covid-19-Epidemie*.; 2020.

7. Anderson R, Donnelly C, Hollingsworth D, et al. *Reproduction Number (R) and Growth Rate (r) of the COVID-19 Epidemic in the UK: Methods of Estimation, Data Sources, Causes of Heterogeneity, and Use as a Guide in Policy Formulation*. The Royal Society; 2020.

8. Yabe T, Tsubouchi K, Fujiwara N, Wada T, Sekimoto Y, Ukkusuri SV. Non-compulsory measures sufficiently reduced human mobility in Tokyo during the COVID-19 epidemic. *Sci Rep*. 2020;10(1):18053.

9. Pan A, Liu L, Wang C, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA*. 2020;323(19):1915-1923.

10. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020;584(7820):257-261.

11. Soltesz K, Gustafsson F, Timpka T, et al. The effect of interventions on COVID-19. *Nature*. 2020;588(7839):E26-E28.

12. Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020. *MMWR Morbidity and Mortality Weekly Report*. 2020;69(42):1522-1527. doi:10.15585/mmwr.mm6942e2

13. Peccia J, Zulli A, Brackney DE, et al. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nat Biotechnol*. 2020;38(10):1164-1167.

14. Karthikeyan S, Ronquillo N, Belda-Ferre P, et al. High-Throughput Wastewater SARS-CoV-2 Detection Enables Forecasting of Community Infection Dynamics in San Diego County.

mSystems. 2021;6(2). doi:10.1128/mSystems.00045-21

15.   Graham KE, Loeb SK, Wolfe MK, et al. SARS-CoV-2 RNA in Wastewater Settled Solids Is
Associated with COVID-19 Cases in a Large Urban Sewershed. *Environ Sci Technol*.
2021;55(1):488-498.

16.   Medema G, Heijnen L, Elsinga G, Italiaander R, Brouwer A. Presence of SARS-
Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the
Early Stage of the Epidemic in The Netherlands. *Environ Sci Technol Lett*. 2020;7(7):511-
516.

17.   Agrawal S, Orschler L, Lackner S. Long-term monitoring of SARS-CoV-2 RNA in
wastewater of the Frankfurt metropolitan area in Southern Germany. *Sci Rep*.
2021;11(1):5372.

18.   Arora S, Nag A, Sethi J, et al. Sewage surveillance for the presence of SARS-CoV-2
genome as a useful wastewater based epidemiology (WBE) tracking tool in India. *Water Sci*
Technol. 2020;82(12):2823-2836.

19.   Haramoto E, Malla B, Thakali O, Kitajima M. First environmental surveillance for the
presence of SARS-CoV-2 RNA in wastewater and river water in Japan. *Sci Total Environ*.
2020;737:140405.

20.   Kaplan EH, Wang D, Wang M, Malik AA, Zulli A, Peccia J. Aligning SARS-CoV-2 indicators
via an epidemic model: application to hospital admissions and RNA detection in sewage
sludge. *Health Care Manag Sci*. Published online October 28, 2020. doi:10.1007/s10729-
020-09525-1

21.   McMahan CS, Self S, Rennert L, et al. COVID-19 Wastewater Epidemiology: A Model to
Estimate Infected Populations. *MedRxiv*. Published online 2020.
https://www.medrxiv.org/content/10.1101/2020.11.05.20226738v1.abstract

22.   Fernandez-Cassi X, Scheidegger A, Bänziger C, et al. Wastewater monitoring outperforms
case numbers as a tool to track COVID-19 incidence dynamics when test positivity rates
are high. doi:10.1101/2021.03.25.21254344

23.   Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
with COVID-2019. *Nature*. 2020;581(7809):465-469.

24.   Han MS, Seong MW, Kim N, et al. Viral RNA Load in Mildly Symptomatic and
Asymptomatic Children with COVID-19, Seoul, South Korea. *Emerg Infect Dis*.
2020;26(10):2497-2499.

25.   Benefield AE, Skrip LA, Clement A, Althouse RA, Chang S, Althouse BM. SARS-CoV-2
viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis
of coronavirus viral load from 66 studies. *medRxiv*. Published online 2020.
https://www.medrxiv.org/content/10.1101/2020.09.28.20202028v1.abstract

26.   Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
Coronavirus–Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199-1207.

27.   Symonds EM, Nguyen KH, Harwood VJ, Breitbart M. Pepper mild mottle virus: A plant

pathogen with a greater purpose in (waste)water treatment development and public health
management. *Water Res*. 2018;144:1-12.

28. Topol A, Wolfe M, White B, Wigginton K, Boehm A. High Throughput pre-analytical
processing of wastewater settled solids for SARS-CoV-2 RNA analyses v1
(protocols.io.btyqnpvw). *protocols.io*. Published online 2021.
doi:10.17504/protocols.io.btyqnpvw

29. Topol A, Wolfe M, Wigginton K, White B, Boehm A. High Throughput RNA Extraction and
PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2 RNA
v1 (protocols.io.btyrnpv6). *protocols.io*. Published online 2021.
doi:10.17504/protocols.io.btyrnpv6

30. Topol A, Wolfe M, White B, Wigginton K, Boehm A. High Throughput SARS-COV-2,
PMMOV, and BCoV quantification in settled solids using digital RT-PCR v1
(protocols.io.btywnpxe). *protocols.io*. Published online 2021.
doi:10.17504/protocols.io.btywnpxe

31. Wolfe MK, Topol A, Knudson A, et al. High-Frequency, High-Throughput Quantification of
SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned Treatment Works
in Northern California Shows Strong Association with COVID-19 Incidence. *mSystems*.
2021;6(5):e0082921.

32. Zhu K, Suttner B, Pickering A, Konstantinidis KT, Brown J. A novel droplet digital PCR
human mtDNA assay for fecal source tracking. *Water Res*. 2020;183:116085.

33. Huggett JF, Novak T, Garson JA, et al. Differential susceptibility of PCR reactions to
inhibitors: an important and unrecognised phenomenon. *BMC Res Notes*. 2008;1:70.

34. Haramoto E, Kitajima M, Kishida N, et al. Occurrence of pepper mild mottle virus in drinking
water sources in Japan. *Appl Environ Microbiol*. 2013;79(23):7413-7418.

35. Zhang T, Breitbart M, Lee WH, et al. RNA Viral Community in Human Feces: Prevalence of
Plant Pathogenic Viruses. *PLoS Biol*. 2005;4(1):e3.

36. Linton NM, Kobayashi T, Yang Y, et al. Incubation period and other epidemiological
characteristics of 2019 novel Coronavirus infections with right truncation: A statistical
analysis of publicly available case data. *J Clin Med Res*. 2020;9(2):538.

37. Cori A, Cauchemez S, Ferguson NM, et al. EpiEstim: estimate time varying reproduction
numbers from epidemic curves. *R package version*. Published online 2019:2-2.

38. Feng S, Roguet A, McClary-Gutierrez JS, et al. Evaluation of sampling frequency and
normalization of SARS-CoV-2 wastewater concentrations for capturing COVID-19 burdens
in the community. *medRxiv*. Published online 2021.
https://www.medrxiv.org/content/10.1101/2021.02.17.21251867v2.abstract

39. Kitajima M, Ahmed W, Bibby K, et al. SARS-CoV-2 in wastewater: State of the knowledge
and research needs. *Sci Total Environ*. 2020;739:139076.

40. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and
MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a

systematic review and meta-analysis. *Lancet Microbe*. 2021;2(1):e13-e22.

41. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected
with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort
study. *BMJ*. 2020;369:m1443.

42. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over
the course of an infection. *J Infect*. 2020;81(3):357-371.

43. Hoffmann T, Alsing J. Faecal shedding models for SARS-CoV-2 RNA amongst hospitalised
patients and implications for wastewater-based epidemiology. *medRxiv*. Published online
2021. https://www.medrxiv.org/content/10.1101/2021.03.16.21253603v1.abstract

44. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet*
Infect Dis. 2020;20(6):656-657.

45. Zhou C, Zhang T, Ren H, et al. Impact of age on duration of viral RNA shedding in patients
with COVID-19. *Aging* . 2020;12(22):22399-22404.

46. Parag KV. Improved estimation of time-varying reproduction numbers at low case incidence
and between epidemic waves. *medRxiv*. Published online 2020.
https://www.medrxiv.org/content/10.1101/2020.09.14.20194589v1.abstract

47. Abbott S, Hellewell J, Thompson RN, et al. Estimating the time-varying reproduction
number of SARS-CoV-2 using national and subnational case counts. *Wellcome Open*
Research. 2020;5:112. doi:10.12688/wellcomeopenres.16006.1

48. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG
antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*.
2020;396(10247):313-319.

49. Stringhini S, Zaballa ME, Perez-Saez J, et al. Seroprevalence of anti-SARS-CoV-2
antibodies after the second pandemic peak. *The Lancet Infectious Diseases*. Published
online 2021. doi:10.1016/s1473-3099(21)00054-2

50. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation
frequency and timing, and stool form in the general population: a prospective study. *Gut*.
1992;33(6):818-824.

51. Thomas KV, Amador A, Baz-Lomba JA, Reid M. Use of Mobile Device Data To Better
Estimate Dynamic Population Size for Wastewater-Based Epidemiology. *Environ Sci*
Technol. 2017;51(19):11363-11370.

52. Kantor RS, Nelson KL, Greenwald HD, Kennedy LC. Challenges in Measuring the
Recovery of SARS-CoV-2 from Wastewater. *Environ Sci Technol*. 2021;55(6):3514-3519.

53. de Oliveira LC, Torres-Franco AF, Lopes BC, et al. Viability of SARS-CoV-2 in river water
and wastewater at different temperatures and solids content. *Water Res*. 2021;195:117002.

54. Bivins A, Greaves J, Fischer R, et al. Persistence of SARS-CoV-2 in Water and
Wastewater. *Environ Sci Technol Lett*. 2020;7(12):937-942.

55. Hokajärvi AM, Rytkönen A, Tiwari A, et al. The detection and stability of the SARS-CoV-2

RNA biomarkers in wastewater influent in Helsinki, Finland. *Sci Total Environ.*
2021;770:145274.

56. Gerrity D, Papp K, Stoker M, Sims A, Frehner W. Early-pandemic wastewater surveillance
of SARS-CoV-2 in Southern Nevada: Methodology, occurrence, and incidence/prevalence
considerations. *Water Res X.* 2021;10:100086.

57. Jahn K, Dreifuss D, Topolsky I, et al. Detection of SARS-CoV-2 variants in Switzerland by
genomic analysis of wastewater samples. *medRxiv.* Published online 2021.
https://www.medrxiv.org/content/10.1101/2021.01.08.21249379v1.abstract

58. Crits-Christoph A, Kantor RS, Olm MR, et al. Genome Sequencing of Sewage Detects
Regionally Prevalent SARS-CoV-2 Variants. *MBio.* 2021;12(1). doi:10.1128/mBio.02703-20

59. Martin J, Klapsa D, Wilton T, et al. Tracking SARS-CoV-2 in Sewage: Evidence of Changes
in Virus Variant Predominance during COVID-19 Pandemic. *Viruses.* 2020;12(10).
doi:10.3390/v12101144

60. Brinkman NE, Fout GS, Keely SP. Retrospective Surveillance of Wastewater To Examine
Seasonal Dynamics of Enterovirus Infections. *mSphere.* 2017;2(3).
doi:10.1128/mSphere.00099-17

61. Kazama S, Masago Y, Tohma K, et al. Temporal dynamics of norovirus determined through
monitoring of municipal wastewater by pyrosequencing and virological surveillance of
gastroenteritis cases. *Water Res.* 2016;92:244-253.

62. McCall C, Wu H, Miyani B, Xagoraraki I. Identification of multiple potential viral diseases in
a large urban center using wastewater surveillance. *Water Res.* 2020;184:116160.

63. dMIQE Group, Huggett JF. The Digital MIQE Guidelines Update: Minimum Information for
Publication of Quantitative Digital PCR Experiments for 2020. *Clin Chem.* 2020;66(8):1012-
1029.

Supplemental Material:

957
Fig. S1: R_{ww} estimation from San Jose (USA) sludge measurements, assuming zero delay
between symptom onset and testing: (A) Measured RNA concentrations of the N, S and ORF1a
genes (blue, green, yellow respectively) between 15 November 2020 and 19 March 2021. (B, C)
Confirmed cases and testing-adjusted cases in Santa Clara county (purple, red) during the
same time period. The testing-adjusted cases describe the number of positive tests / total
number of tests per day, normalized by the mean number of tests per day in Santa Clara county

during the study period. In contrast to Fig. 2 in the main text, the delay between symptom onset
and testing was assumed 0, rather than the same as for case reporting. (D) The estimated
infection incidence per day from normalized RNA concentrations (top), case reports (middle)
and testing-adjusted cases (bottom). The gene copies per gram dry weight were normalized by
the lowest measured value ($N*M$ = 2663.7 gc/g-dry weight per infection/day). The ribbons
indicate the mean ± standard deviation across 1000 bootstrap replicates. (E) The estimated R_{ww}
compared to R_{cc} from confirmed cases (top) and testing-adjusted cases (bottom). The colored
line indicates the point estimate on the original data, and the ribbons the 95% confidence
interval across 1000 bootstrap replicates.
973

974
Fig. S2: R_ww estimation from San Jose (USA) sludge measurements, accounting for case
reporting errors: (A) Measured RNA concentrations of the N, S and ORF1a genes (blue, green,
yellow respectively) between 15 November 2020 and 19 March 2021. (B, C) Confirmed cases

and testing-adjusted cases in Santa Clara county (purple, red) during the same time period. In
contrast to Fig. 2 in the main text, the missing cases on Dec. 30th were set to 1000 in panel (B).
The testing-adjusted cases describe the number of positive tests / total number of tests per day,
normalized by the mean number of tests per day in Santa Clara county during the study period.
(D) The estimated infection incidence per day from normalized RNA concentrations (top), case
reports (middle) and testing-adjusted cases (bottom). The gene copies per gram dry weight
were normalized by the lowest measured value ($N*M$ = 2663.7 gc/g-dry weight per
infection/day). The ribbons indicate the mean ± standard deviation across 1000 bootstrap
replicates. (E) The estimated R_{ww} compared to R_{cc} from confirmed cases (top) and testing-
adjusted cases (bottom). The colored line indicates the point estimate on the original data, and
the ribbons the 95% confidence interval across 1000 bootstrap replicates.

989
Fig. S3: The estimated R_{ww} based on N gene measurements in San Jose (black line, grey
990
95% confidence intervals) compared to different R_{cc} estimates for Santa Clara county
991
from the California COVID assessment tool (CalCat). The R_{ww} estimate from Fig. 2D was
992
compared to 6 methods to estimate R_{cc}, indicated by the color and panel title. "ETH" refers to
993
the pipeline of Huisman et al. [2] applied to the daily confirmed case data from Santa Clara
994

995   county, i.e. the same comparison as shown in Fig. 2D. We excluded the SEIR model based
996   estimates included on the CalCat website (since these performed visibly worse than the other
997   methods).

998
Fig. S4: The effect of sampling frequency on the R$_{ww}$ estimates in Zurich and San Jose.
The data stems from measurements of the N1 marker for Zurich between 2020-11-22 and
2021-01-11, and the S gene for San Jose between 2020-11-15 and 2021-03-19. The row
indicates the number of samples taken per week (1, 2, 3, 5), while the colors indicate the

sampling schedule: MTWTFSS corresponds to daily sampling, MTWTF sampling during the
working week, MWF Mon-Wed-Fri, TTS Tue-Thu-Sat, MT Mon-Thu, TF Tue-Fri, WS Wed-Sat,
M Monday, W Wednesday, F Friday. The colored line indicates the point estimate on the
original data, and the ribbons the 95% confidence interval across 1000 bootstrap replicates.
1007

1008   **Table S1: The match between the daily and further subsampled R_{ww} traces for Zurich.** The
1009   data stems from measurements of the N1 marker for Zurich between 2020-11-22 and 2021-01-
1010   11. All traces are compared to the daily sampling; MTWTF corresponds to sampling during the
1011   working week, MWF Mon-Wed-Fri, TTS Tue-Thu-Sat, MT Mon-Thu, TF Tue-Fri, WS Wed-Sat,
1012   M Monday, W Wednesday, F Friday.
1013

	MTWTF	MWF	TTS	MT	TF	WS	M	W	F
RMSE	0.03	0.04	0.03	0.12	0.09	0.06	0.17	0.06	0.18
Coverage	1.00	0.97	0.94	0.78	0.83	0.92	0.53	0.83	0.61
MAPE	0.02	0.03	0.02	0.09	0.07	0.05	0.12	0.04	0.17

1014

1015   **Table S2: The match between the daily and further subsampled R_{ww} traces for San Jose.**
1016   The data stems from the S gene measurements for San Jose. All traces are compared to the
1017   daily sampling; MTWTF corresponds to sampling during the working week, MWF Mon-Wed-Fri,
1018   TTS Tue-Thu-Sat, MT Mon-Thu, TF Tue-Fri, WS Wed-Sat, M Monday, W Wednesday, F Friday.
1019

	MTWTF	MWF	TTS	MT	TF	WS	M	W	F
RMSE	0.05	0.09	0.08	0.15	0.06	0.16	0.13	0.13	0.08
Coverage	0.95	0.88	0.91	0.83	0.93	0.60	0.76	0.68	0.84
MAPE	0.05	0.08	0.07	0.15	0.06	0.14	0.11	0.11	0.07

1020
1021
1022

1023
Fig. S5: The impact of the shedding load distribution on (A) the inferred infection
incidence and (B) R_{ww} estimation from the Zurich wastewater data. The results are
compared for four SLDs (see Methods): the Benefield SLD upon symptom onset (Incubation +
Benefield) [25], the Han SLD upon symptom onset (Incubation + Han) [24,25], shedding only on the
day of symptom onset (Incubation only), shedding only on the day of death (Incubation + Death)
[36]. The error bars (A; mean ± standard deviation) and 95% confidence intervals (B) are based
on 50 bootstrap replicates per condition.
1031

1032

Fig. S6: The effect of data normalization on the estimated R$_{ww}$ in Zurich. We calculated R$_{ww}$
from the measured N1 marker indicating the N gene copy loads, normalized in four different
ways: by 1x10^{12} gc per infection (the order of magnitude of the lowest measured concentration),
by 5x10^{10} gc per infection (roughly rescaled to case incidence), by 1x10^{5} gc per infection (to
cover the space of possible orders of magnitude), no normalization. **(A)** After normalization the
measurements were deconvolved, and rescaled back to the original magnitude (multiplied by
the normalization factor) to illustrate differences in the inferred infection incidence. **(B)** The

resulting R_{ww} estimates differ both in the mean (due to the deconvolution illustrated in A) and
width of the uncertainty interval. The results are compared for four SLDs (panels; see Methods):
the Benefield SLD upon symptom onset (Incubation + Benefield) [25], the Han SLD upon
symptom onset (Incubation + Han) [24,25], shedding only on the day of symptom onset (Incubation
only), shedding only on the day of death (Incubation + Death) [36]. The 95% confidence intervals
(B) are based on 50 bootstrap replicates per condition.

1046

1047
Fig. S7: Coverage between R_{cc} and R_{ww} for different shedding load distributions. We
scanned across different parameter pairs (mean, standard deviation in days) for the SLD from
time since infection. For the city of Zurich, the R_{ww} from N1 loads in wastewater was compared
to that of confirmed cases in the catchment. For San Jose, we compared S gene concentrations
to confirmed cases in Santa Clara County. The contour lines show SLD parameter pairs with
equal coverage, in steps of 10% of the optimum value. In each comparison (grid-point) the 95%
confidence intervals of R_{cc} and R_{ww} are based on 50 bootstrap replicates.

1055

1056
Fig. S8: MAPE between R_{cc} and R_{ww} for different shedding load distributions. We scanned
across different parameter pairs (mean, standard deviation in days) for the SLD from time since
infection. For the city of Zurich, the R_{ww} from N1 loads in wastewater was compared to that of
confirmed cases in the catchment. For San Jose, we compared S gene concentrations to
confirmed cases in Santa Clara County. The contour lines show SLD parameter pairs with equal
MAPE, in steps of 10% of the optimum value.

1063

1064
Fig. S9: The optimal shedding load distributions for Zurich and two counterexamples.
Counterexample A has a mean of 2 days and standard deviation of 5 days; Counterexample B a
mean of 13 days, and a standard deviation of 5 days. **(A)** The SLDs and their associated
cumulative distribution functions. Although the SLDs differ when optimized for RMSE,
Coverage, or MAPE, the median (i.e. the time after which they reach half their overall probability
mass) is very comparable. **(B)** The resulting R_{ww} estimates for Zurich are highly similar for
RMSE, Coverage, and MAPE based optimal SLDs; but differ substantially for the two
counterexamples. The illustrated 95% confidence intervals of R_{ww} are based on 50 bootstrap
replicates.

1074

Fig. S10: RMSE between R_{cc} and R_{ww} for different shedding load distributions from symptom onset. We scanned across different parameter pairs (mean, standard deviation in days) for the SLD from time since symptom onset. For the city of Zurich, the Re from N1 loads in wastewater was compared to that of confirmed cases in the catchment. For San Jose, we compared S gene concentrations to confirmed cases in Santa Clara County. The incubation period is assumed gamma distributed with mean 5.3, and standard deviation 3.2. The contour lines show SLD parameter pairs with equal RMSE, in steps of 10% of the optimum value.

Table S3: Parameters of the optimal shedding distribution from symptom onset. We scanned across different (mean, standard deviation) parameter pairs for the SLD from time since symptom onset. For the city of Zurich, the R_{ww} from N1 loads in wastewater was compared to that of confirmed cases in the catchment. For San Jose, we compared S gene concentrations to confirmed cases in Santa Clara County. For all RMSE values of the scan see Fig. S9. All parameters are in units of days. For the coverage, the 95% confidence intervals of R_{cc} and R_{ww} were based on 50 bootstrap replicates in each comparison.

Comparison Method	Optimal pair (mean; sd)	Mean within 10% of the optimum	SD within 10% of the optimum
RMSE (Zurich)	(5.5; 10)	[1.5, 7]	[0.5, 10]
Coverage (Zurich)	(3.5; 5)	[1.5, 8]	[0.5, 10]
MAPE (Zurich)	(5.5; 10)	[2, 6]	[0.5, 10]
RMSE (San Jose)	(3; 0.5)	[1, 5]	[0.5, 9]
Coverage (San Jose)	(0.5; 0.5)	[0.5, 6]	[0.5, 10]
MAPE (San Jose)	(1; 0.5)	[0.5, 3]	[0.5, 10]

1096 **Table S4: Primer and Probes**

1097

Site	Target	Primer/Probe	Sequence
Zurich	N1	Forward	GACCCCAAAATCAGCGAAAT
		Reverse	GACCCCAAAATCAGCGAAAT
		Probe	ACCCCGCATTACGTTTGGTGGACC (5' FAM/ZEN/3' IBFQ)
	N2	Forward	TTACAAACATTGGCCGCAAA
		Reverse	GCGCGACATTCCGAAGAA
		Probe	ACAATTTGCCCCCAGCGCTTCAG (5' FAM/HEX/ZEN/ 3' IBFQ)
	PMMoV	Forward	GAGTGGTTTGACCTTAACGTTTGA
		Reverse	TTGTCGGTTGCAATGCAAGT
		Probe	CCTACCGAAGCAAATG (5' FAM/3' MGB)
San Jose	N Gene	Forward	CATTACGTTTGGTGGACCCT
		Reverse	CCTTGCCATGTTGAGTGAGA
		Probe	CGCGATCAAAACAACGTCGG (5' FAM/ZEN/3' IBFQ)
	S Gene	Forward	CAGACTAATTCTCCTCGGCG
		Reverse	TGCACCAAGTGACATAGTGT
		Probe	AGCTAGTCAATCCATCATTGCCT (5' HEX/ZEN/3' IBFQ)
	ORF1a	Forward	CAGAACTGGAACCACCTTGT
		Reverse	TACAGTTGAATTGGCAGGCA
		Probe	TGCCACAGTACGTCTACAAGC (5' FAM or HEX/ZEN/3' IBFQ)

PMMoV	Forward	GAGTGGTTTGACCTTAACGTTTGA
	Reverse	TTGTCGGTTGCAATGCAAGT
	Probe	CCTACCGAAGCAAATG (5' HEX/ZEN/3' IBFQ)
BCoV	Forward	CTGGAAGTTGGTGGAGTT
	Reverse	ATTATCGGCCTAACATACATC
	Probe	CCTTCATATCTATACACATCAAGTTGTT (5' FAM/ZEN/3' IBFQ)

1098
1099
1100

1101

1102

1103

Fig. S11: Fluorescence plots from the Stilla Naica Crystal Droplet PCR used for the wastewater samples from Zurich collected after 23 September 2020 from positive (top) and negative (bottom) experimental results. Droplets positive for N1 (blue) and N2 (brown) and both N1 and N2 (purple). RPP30 markers, detectable as elevated fluorescence in Green channel, are included in the commercial assay used, but are not further analyzed.

1109

1110

1111

1112

Fig. S12: Fluorescence plots from the Bio-Rad QX200 used for the wastewater samples.
Samples from Zurich collected from 03-20 September 2020 are shown in positive (top) and
negative (middle) experimental results. Droplets positive for N1 (red) and N2 (yellow) and both
N1 and N2 (brown) markers. Negative (bottom) experimental results are also shown for San
Jose Corresponding positive experimental results are provided in the reference of the
associated protocol [30].

1119

1120

1121

1122

ITEM TO CHECK	PROVIDED	COMMENT
	Y/N	
1. SPECIMEN		
Detailed description of specimen type and numbers	Y	Methods of Main Text
Sampling procedure (including time to storage)	Y	Methods of Main Text
Sample aliquotation, storage conditions and duration	Y	Methods of Main Text
2. NUCLEIC ACID EXTRACTION		
Description of extraction method including amount of sample	Y	Methods of Main Text
Volume of solvent used to elute/resuspend extract	Y	Methods of Main Text
Number of extraction replicates	Y	Methods of Main Text
Extraction blanks included?	Y	Methods of Main Text
3. NUCLEIC ACID ASSESSMENT AND STORAGE		
Method to evaluate quality of nucleic acids	N	Not Done
Method to evaluate quantity of nucleic acids (including molecular	N	Not Done
Storage conditions: temperature, concentration, duration, buffer, aliquots	Y	Methods of Main Text
Clear description of dilution steps used to prepare working DNA solution	Y	Methods of Main Text
4. NUCLEIC ACID MODIFICATION		
Template modification (digestion, sonication, pre-amplification,	N	NA
Details of repurification following modification if performed	Y	No Repurification for Zurich Samples, Zymo Column for San Jose Samples Described in Methods of Main Text
5. REVERSE TRANSCRIPTION		
cDNA priming method and concentration	N	NA
One or two step protocol (include reaction details for two step)	Y	Methods of Main Text
Amount of RNA added per reaction	Y	Methods of Main Text
Detailed reaction components and conditions	Y	Supplemental Information
Estimated copies measured with and without addition of RT*	N	Not Done
Manufacturer of reagents used with catalogue and lot numbers	N	Reagents, Manufacturers, and Catalogue Numbers Reported in Supplemental Material. Lot Numbers are Not Reported
Storage of cDNA: temperature, concentration, duration, buffer and	Y	NA
6. dPCR OLIGONUCLEOTIDES DESIGN AND TARGET INFORMATION		
Sequence accession number or official gene symbol	Y	Published Reference (Zurich) or Supplemental (San Jose)
Method (software) used for design and *in silico* verification	Y	Published Reference (Zurich) or Supplemental (San Jose)
Location of amplicon	Y	Published Reference (Zurich) or Supplemental (San Jose)
Amplicon length	Y	Published Reference (Zurich) or Supplemental (San Jose)
Primer and probe sequences (or amplicon context sequence)**	Y	Supplemental Information
Location and identity of any modifications	Y	NA
Manufacturer of oligonucleotides	Y	Supplemental Information
7. dPCR PROTOCOL		
Manufacturer of dPCR instrument and instrument model	Y	Supplemental Information
Buffer/kit manufacturer with catalogue and lot number	Y	Supplemental Information
Primer and probe concentration	Y	Supplemental Information
Pre-reaction volume and composition (incl. amount of template	Y	Supplemental Information
Template treatment (initial heating or chemical denaturation)	N	NA
Polymerase identity and concentration, Mg++ and dNTP concentrations***	N	Included in Kit Manuals
Complete thermocycling parameters	Y	Supplemental Information
8. ASSAY VALIDATION		
Details of optimisation performed	N	Commercial Kit, Followed Manufacturer's Instructions
Analytical specificity (vs. related sequences) and limit of blank (LOB)	N	Not done (Zurich) or Supplemental (San Jose)
Analytical sensitivity/LoD and how this was evaluated	Y	Methods of Main Text
Testing for inhibitors (from biological matrix/extraction)	Y	Methods of Main Text
9. DATA ANALYSIS		
Description of dPCR experimental design	Y	Methods of Main Text
Comprehensive details negative and positive of controls (whether a	Y	Methods of Main Text
Partition classification method (thresholding)	Y	Supplemental Information
Examples of positive and negative experimental results (including	Y	Supplemental Information
Description of technical replication	Y	Methods of Main Text
Repeatability (intra-experiment variation)	Y	Supplemental Information
Reproducibility (inter-experiment/user/lab etc. variation)	N	Assays were only completed within one laboratory
Number of partitions measured (average and standard deviation)	Y	Supplemental Information
Partition volume	Y	Reported by Manufacturer
Copies per partition (λ or equivalent) (average and standard deviation)	Y	Supplemental Information
dPCR analysis program (source, version)	Y	Methods of Main Text
Description of normalisation method	N	NA
Statistical methods used for analysis	Y	Methods of Main Text
Data transparency	raw data available on request:	Data Availability Statement Includes Resources for Zurich Measurements, Contact Information for San Jose Measurements

1123

1124 **Table S5: dMIQE Checklist [63] for RT-dPCR assays targeting SARS-CoV-2 gene markers**
1125 **N1 and N2 (Zurich Site) and S, N, and Orf1a (San Jose Site).** Checklist is not included for
1126 other RT-qPCR (PMMoV, Zurich Site) or RT-dPCR (BCoV, PMMoV, San Jose) Assays.

Supplemental Results:

Quality Control:

Zurich, Switzerland. One sample (11 October) was removed from analysis because the dilute sample (1:10) was below LOQ and the undiluted sample was inhibited, as defined by recovery of less than 80% of the synthetic SARS-CoV-2 RNA added in.

PMMoV concentrations were obtained for all dates except October 4. Mean (standard deviation) PMMoV loads were 16.5 (0.12) $\log_{10}$ (gc/day). All PMMoV loads fell within 3 standard deviations of the mean, consistent with a normal distribution, except on 29 October (16.1 $\log_{10}$ gc/day). The sample was subsequently removed from further analysis.

San Jose, California, USA. From San Jose Wastewater Treatment Plant (San Jose, California, USA), daily samples were collected and processed throughout. PMMoV concentrations were mean (standard deviation) 8.9 (0.20) $\log_{10}$ (gc/g-dry weight). On two days (03 January 2021, 18 February 2021), PMMoV concentrations exceeded the mean plus three times the standard deviation. On one day (19 March 2021), PMMoV concentrations fell below the mean minus three times the standard deviation. These three samples were excluded from further analysis. All samples met criteria for inclusion based on BCoV concentrations, which were all greater than 10% of the expected concentrations based on the amount added.

Supplemental Methods:

Managing PCR inhibition in San Jose sludge samples:

We diluted the solids in DNA/RNA Shield (Zymo Research, Irvine, CA, USA) (hereafter referred to as "diluent") prior to RNA extraction, inhibitor removal, and RT-dPCR, as described in the main text. This dilution was necessary as direct RNA extraction from the solids contained inhibitors so dilution of the RNA template prior to RT-dPCR was required [15].To determine an optimal concentration of solids to add to the diluent (mg wet weight / mL diluent) to reduce inhibition, but retain reasonable sensitivity, we quantified SARS-CoV-2 RNA in solutions with solids concentrations from 7.5 mg/mL to 150 mg/mL, where we used the exact methods described in the main text. We aimed to identify the highest concentrations of solids in solution that did not show inhibition. Representative results from two different samples from San Jose are shown in Figure S13 where concentrations of SARS-CoV-2 RNA per g dry weight of solids is shown for different starting concentrations of solids in diluent. Note that the numbers on the y-axis are directly comparable between solutions, as we account for the different mass of solids in the dimensional analysis to derive the SARS-CoV-2 RNA concentration. The relatively lower concentrations for SARS-CoV-2 RNA for solutions of 150 mg/mL suggest the presence of inhibition at this relatively high solids concentration. Concentrations are relatively similar among the lower concentration solutions suggesting that starting at 75 mg/mL, inhibition is mostly alleviated. Only one gene target from one of the samples (the N gene in sample A shown in the top graph) showed slightly higher concentrations in more dilute solutions. Given these results we therefore moved forward using 75 mg/mL for the method.

1165

1166 **Figure S13.** Representative results from inhibition titration experiments with two samples from
1167 San Jose. The x-axis shows the concentration of solids (wet weight) added to the DNA/RNA
1168 Shield diluent in units of mg/mL. The y-axis shows the concentration of the three SARS-CoV-2
1169 RNA targets in the solids in units of gc/g dry weight. Error bars represent standard deviations as
1170 total error from the dPCR instrument's software.

1171